Omeros Corp (OMER)

$7.31 +0.01 (0.14%)
Market Cap 423.87M
Revenue (ttm) 0.00
Net Income (ttm) -156.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -1.03
Volume 367,500
Avg Vol 674,406
Day's Range N/A - N/A
Shares Out 58.06M
Stochastic %K 69%
Beta 2.35
Analysts Sell
Price Target $22.50

Latest News on OMER

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 11, 2025, 3:06 PM EDT - 15 days ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 10, 2025, 9:10 AM EDT - 16 days ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Apr 8, 2025, 9:00 AM EDT - 18 days ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 8:57 PM EDT - 25 days ago

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 31, 2025, 4:02 PM EDT - 26 days ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Mar 28, 2025, 7:39 AM EDT - 4 weeks ago

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 26, 2025, 9:15 AM EDT - 4 weeks ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Mar 21, 2025, 9:15 AM EDT - 5 weeks ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

Feb 24, 2025, 4:44 PM EST - 2 months ago

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 20, 2025, 9:10 AM EST - 2 months ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 14, 2025, 9:00 AM EST - 2 months ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Feb 10, 2025, 9:00 AM EST - 2 months ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Jan 16, 2025, 9:15 AM EST - 3 months ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Dec 19, 2024, 12:28 PM EST - 4 months ago

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 19, 2024, 9:15 AM EST - 4 months ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Dec 10, 2024, 8:45 AM EST - 4 months ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Dec 2, 2024, 8:45 AM EST - 5 months ago

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Nov 21, 2024, 9:15 AM EST - 5 months ago

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 10:22 PM EST - 5 months ago

Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript

Omeros Corporation Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:02 PM EST - 5 months ago

Omeros Corporation Reports Third Quarter 2024 Financial Results

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Nov 11, 2024, 4:11 PM EST - 5 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Oct 24, 2024, 8:45 AM EDT - 6 months ago

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 1:05 AM EDT - 9 months ago

Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript

Omeros Corporation Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:02 PM EDT - 9 months ago

Omeros Corporation Reports Second Quarter 2024 Financial Results

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Aug 5, 2024, 4:02 PM EDT - 9 months ago

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Jun 4, 2024, 9:00 AM EDT - 11 months ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028

Jun 3, 2024, 9:00 AM EDT - 11 months ago

Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028

Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript

May 15, 2024, 7:23 PM EDT - 1 year ago

Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript

Omeros Corporation Reports First Quarter 2024 Financial Results

May 15, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports First Quarter 2024 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024

May 10, 2024, 8:50 AM EDT - 1 year ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024

Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress

May 9, 2024, 8:50 AM EDT - 1 year ago

Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress

Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript

Apr 1, 2024, 8:09 PM EDT - 1 year ago

Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

Apr 1, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024

Mar 27, 2024, 8:30 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024

Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Feb 20, 2024, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust

Feb 1, 2024, 9:11 AM EST - 1 year ago

Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust

Omeros: Why It Is Worthwhile To Bet On Narsoplimab

Nov 27, 2023, 1:18 AM EST - 1 year ago

Omeros: Why It Is Worthwhile To Bet On Narsoplimab

Omeros Corporation (OMER) Q3 2023 Earnings Call Transcript

Nov 10, 2023, 10:32 AM EST - 1 year ago

Omeros Corporation (OMER) Q3 2023 Earnings Call Transcript

Omeros Corporation Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:02 PM EST - 1 year ago

Omeros Corporation Reports Third Quarter 2023 Financial Results

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023

Nov 6, 2023, 8:00 AM EST - 1 year ago

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023

Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Nov 3, 2023, 9:05 AM EDT - 1 year ago

Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Oct 19, 2023, 8:30 AM EDT - 1 year ago

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Omeros to terminate kidney disease trial as therapy fails late-stage study

Oct 16, 2023, 8:02 AM EDT - 1 year ago

Omeros to terminate kidney disease trial as therapy fails late-stage study

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

Oct 16, 2023, 7:30 AM EDT - 1 year ago

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

Omeros: Betting Big On Narsoplimab, We Are Still A Buyer

Aug 23, 2023, 7:30 AM EDT - 1 year ago

Omeros: Betting Big On Narsoplimab, We Are Still A Buyer

Omeros Corporation (OMER) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 1:28 PM EDT - 1 year ago

Omeros Corporation (OMER) Q2 2023 Earnings Call Transcript

Omeros Corporation Reports Second Quarter 2023 Financial Results

Aug 9, 2023, 8:00 AM EDT - 1 year ago

Omeros Corporation Reports Second Quarter 2023 Financial Results

Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023

Aug 4, 2023, 8:00 AM EDT - 1 year ago

Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023

Omeros Corporation - Still Looking Too Risky For A Buy Rating

Jul 21, 2023, 5:06 PM EDT - 1 year ago

Omeros Corporation - Still Looking Too Risky For A Buy Rating

Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress

Jun 12, 2023, 8:45 AM EDT - 2 years ago

Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress